Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multi-centered, Randomized, Double-blind, Placebo-controlled, Parallel Group, Three Sequential Part Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

NCT03819881 is registered in ClinicalTrials.gov with Siolta Therapeutics, Inc. as lead sponsor.

NCT NCT03819881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03819881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multi-centered, Randomized, Double-blind, Placebo-controlled, Parallel Group, Three Sequential Part Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy
Lead sponsor
Siolta Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
October 10, 2018
Completion date
November 30, 2019
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atopic immunoglobulin e-mediated allergic disorder